A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
A 12-MONTH OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJECTS 1 MONTH TO 16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES AND PEDIATRIC AND ADULT SUBJECTS 5 TO 65 YEARS OF AGE WITH PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Listed as NCT01463306, this PHASE3 trial focuses on Epilepsy, Partial Seizures and Epilepsy, Primary Generalized Tonic-Clonic Seizures and remains completed. Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc., it has been updated 39 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
39 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Feb 2021 — Dec 2021 [monthly]
Completed PHASE3
▶ Show 34 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Mar 2020 — Sep 2020 [monthly]
Completed PHASE3
-
Jan 2020 — Mar 2020 [monthly]
Completed PHASE3
-
Dec 2019 — Jan 2020 [monthly]
Completed PHASE3
-
Oct 2019 — Dec 2019 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Aug 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE3
-
Jul 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
May 2019 — Jul 2019 [monthly]
Recruiting PHASE3
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE3
-
Mar 2019 — Apr 2019 [monthly]
Recruiting PHASE3
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE3
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE3
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE3
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE3
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE3
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Apr 2018 — May 2018 [monthly]
Recruiting PHASE3
-
Mar 2018 — Apr 2018 [monthly]
Recruiting PHASE3
-
Feb 2018 — Mar 2018 [monthly]
Recruiting PHASE3
-
Dec 2017 — Feb 2018 [monthly]
Recruiting PHASE3
-
Nov 2017 — Dec 2017 [monthly]
Recruiting PHASE3
-
Oct 2017 — Nov 2017 [monthly]
Recruiting PHASE3
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
Aug 2017 — Sep 2017 [monthly]
Recruiting PHASE3
-
Jun 2017 — Aug 2017 [monthly]
Recruiting PHASE3
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE3
-
Apr 2017 — May 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Feb 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Akron, United States , Ancona, Italy , Ankara, Turkey (Türkiye) , Athens, Greece , Balassagyarmat, Hungary , Bangkoknoi, Thailand , Barnaul, Russia , Beirut, Lebanon , Belgrade, Serbia , Bijelo Polje, Montenegro and 98 more locations